Compare AIXI & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIXI | XAIR |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.5M |
| IPO Year | 2023 | N/A |
| Metric | AIXI | XAIR |
|---|---|---|
| Price | $0.65 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 189.8K | 160.6K |
| Earning Date | 12-26-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,314,315.00 | $5,802,000.00 |
| Revenue This Year | $26.84 | $128.45 |
| Revenue Next Year | N/A | $153.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.84 | ★ 147.74 |
| 52 Week Low | $0.60 | $1.00 |
| 52 Week High | $6.65 | $11.20 |
| Indicator | AIXI | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 32.96 |
| Support Level | $0.64 | $1.00 |
| Resistance Level | $0.71 | $1.31 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 19.98 | 32.94 |
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.